Accumark Labs

CERTIFICATE OF ANALYSIS

Triumphant Labs
4858 W Pico Blvd #1031 Los Angeles, CA 90019
hi@triumphantlabs.com
http://triumphantlabs.com

SAMPLE NAME:	Eloralintide 5mg
SAMPLE CODE:	YF92-X5VZ
RECEIVED DATE:	10/26/2026
PUBLISHED DATE:	10/28/2026



DECLARED IDENTITY	Eloralintide
MATRIX TYPE:	PEPTIDE
SAMPLE NAME:	Eloralintide 5mg
SAMPLE SIZE:	5.0 mg
Nº LOT CODE:	KEI_ELO5_2610


Variance
3 Vials

6.14 mg
Total Quantity

99.73%
Total Blend Purity

Sample	Test	Specification	Result	Status
Eloralintide	IDENTITY	Eloralintide	Conforms 3/3	Conforms 3/3
Eloralintide	QUANTITY	As measured	mean 6.14 mg · SD 0.09 · %RSD 1.47% · n=3	MEASURED
Eloralintide	PURITY	≥ 98 %	mean 99.73% · SD 0.08 · %RSD 0.08% · n=3	CONFORMS

HPLC Chromatogram Report



RESULTS REVIEWED BY:

Anthony Burke PhD
Lab Manager
10/28/2026

RESULTS CERTIFIED BY:

Dr. Levi Fried MD
Lab Director
10/28/2026

ACCUMARKLABS.COM
YF92-X5VZ
10/28/2026

Accumark Labs

CERTIFICATE OF ANALYSIS

Triumphant Labs
4858 W Pico Blvd #1031 Los Angeles, CA 90019
hi@triumphantlabs.com
http://triumphantlabs.com

SAMPLE NAME:	Eloralintide 5mg
SAMPLE CODE:	YF92-X5VZ
RECEIVED DATE:	10/26/2026
PUBLISHED DATE:	10/28/2026

VIAL	Eloralintide		
	Identity	Quantity mg	Purity %
Vial 1	Conforms	6.039 mg	**99.822%**
Vial 6	Conforms	6.209 mg	**99.681%**
Vial 7	Conforms	6.178 mg	**99.692%**

RESULTS CERTIFIED BY:

Anthony Burke PhD
Lab Manager
10/28/2026

RESULTS CERTIFIED BY:

Dr. Levi Fried MD
Lab Director
10/28/2026

ACCUMARKLABS.COM
YF92-X5VZ
10/28/2026

Accumark Labs

CERTIFICATE OF ANALYSIS

Triumphant Labs
4858 W Pico Blvd #1031 Los Angeles, CA 90019
hi@triumphantlabs.com
http://triumphantlabs.com

SAMPLE NAME:	Eloralintide 5mg
SAMPLE CODE:	YF92-X5VZ
RECEIVED DATE:	10/26/2026
PUBLISHED DATE:	10/28/2026

Endotoxin USP85 LAL

Basis: USP<85> Parenteral 350 EU/dose | Assumed 70 kg, whole vial per dose

Test	Specification (EU/vial)	Result (EU/vial)	LOQ (EU/vial)	Verdict
Endotoxin USP85 LAL	< 350	< 25	25	**Conforms**

Method: Endotoxin testing performed using Limulus Amebocyte Lysate assay in accordance with USP <85> under validated laboratory conditions. LOD 0.05 EU/mL.

Basis Endotoxin specification is set assuming the full contents of the vial are administered in one dose.
Reporting A result below 350 EU/vial means the USP<85> safe limit for a 70 kg adult will not be exceeded, regardless of how the vial is dosed.

Rapid Sterility Screening (PCR)

Test	Specification	Result	Unit	Verdict
Rapid Sterility Screening (PCR)	Not Detected	Not Detected		**Conforms**

Method: Rapid sterility screening performed by real-time polymerase chain reaction (qPCR) targeting conserved microbial DNA sequences under validated laboratory conditions.

Heavy Metals - Elemental Impurities

Basis: USP<232> Parenteral PDE | Assumed MDD 25mg / day

Test	Specification (µg/g)	Result (µg/g)	LOQ (µg/g)	Verdict
Lead	≤ 200	3.628	3.2	**Conforms**
Arsenic	≤ 600	< 55	55	**Conforms**
Cadmium	≤ 80	< 40	40	**Conforms**
Mercury	≤ 120	< 40	40	**Conforms**

Method: MP-AES | Sample Prep: Hot block acid digestion of 100 mg of sample with concentrated nitric acid and hydrogen peroxide, loosely capped, diluted to 10 mL.

Basis: Elemental impurity limits are derived from the USP<232> parenteral permitted daily exposure values converted to a concentration basis at the stated maximum daily dose.
Assumed MDD: Concentration limits are derived from the USP<232> parenteral permitted daily exposures — As 15 µg/day, Cd 2 µg/day, Hg 3 µg/day, Pb 5 µg/day — at an assumed maximum daily dose of 25 mg of total drug product (API plus excipient)/day, giving specification limits of As 600 µg/g, Cd 80 µg/g, Hg 120 µg/g, and Pb 200 µg/g. Limits scale inversely with dose; products administered above the assumed MDD require proportionally lower concentration limits.

Fentanyl Screening

Basis: Qualitative lateral-flow immunoassay | Strip detection threshold 200 ng/mL in prepared solution

Test	Specification	Result	Unit	Verdict
Fentanyl	Not Detected	Not Detected		**Conforms**

Method: Lateral-flow immunoassay test strip | Sample Prep: Aqueous reconstitution prepared ; test strip immersed directly per manufacturer procedure

Reporting Fentanyl screening is qualitative. Results are reported as Not Detected or Detected relative to the test strip's stated detection threshold; no numeric concentration is measured or implied. Not Detected indicates fentanyl was not present above that threshold in the prepared sample solution.

RESULTS CERTIFIED BY:

Anthony Burke PhD
Lab Manager
10/28/2026

RESULTS CERTIFIED BY:

Dr. Levi Fried MD
Lab Director
10/28/2026

ACCUMARKLABS.COM
YF92-X5VZ
10/28/2026